Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Seres Therapeutics, Inc.

MCRB Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Seres Therapeutics, Inc. had $0.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’52.7% a year on average.

Add to portfolio Download report

Last close Β· Oct 23, 2026

$2.09

1.9%

What Seres Therapeutics, Inc. does

MCRB Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
Seres Therapeutics, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 12, 2026
Accession Β· CIK
0001193125-26-103276 Β· 0001609809

Earnings calendar Β· Seres Therapeutics, Inc.

Every quarter, companies publish how much they sold and earned. These are the days Seres Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 4, 2026

Wednesday Β· in 9 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$1.34
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 5, 2026 Q2 '26 Before the market opens 8-K β†—
May 5, 2026 Q1 '26 Before the market opens 8-K β†—
Mar 12, 2026 Q4 '25 Before the market opens 8-K β†—
Nov 5, 2025 Q3 '25 Before the market opens 8-K β†—
Aug 6, 2025 Q2 '25 Before the market opens 8-K β†—
May 7, 2025 Q1 '25 Before the market opens 8-K β†—
Jan 9, 2025 Q4 '24 Time not announced 8-K β†—
Nov 7, 2024 Q3 '24 Time not announced 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Seres Therapeutics, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

2 strengths 1 to watch

1.Sales and profit

See section β†’
  • Seres Therapeutics, Inc. had $0.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’52.7% a year on average.
  • Its operating margin was βˆ’11,910.1%: of every 100 in sales, about βˆ’11,910 is left after running the business.
  • Seres Therapeutics, Inc. made $5.7M of net profit in fiscal 2025.

Seres Therapeutics, Inc. in 30 seconds

Good So-so Weak

Good

Does it make a profit?

721.9%

Yes. It keeps 721.9% of every sale as profit.

Good

Does profit turn into cash?

109.6%

Yes. 109.6% of sales ends up as free cash.

So-so

How healthy are the accounts?

5 / 7

Mixed. It passes 5 of 7 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$20.4M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$2.45 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Seres Therapeutics, Inc. had $0.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’52.7% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

KIRA Β· Its operating margin was βˆ’11,910.1%: of every 100 in sales, about βˆ’11,910 is left after running the business.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Seres Therapeutics, Inc. made $5.7M of net profit in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was $0.9M in fiscal 2025, 109.6% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Seres Therapeutics, Inc. had $0.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’52.7% a year on average. Its operating margin was βˆ’11,910.1%: of every 100 in sales, about βˆ’11,910 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Seres Therapeutics, Inc. made $5.7M of net profit in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was $0.9M in fiscal 2025, 109.6% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders sold $0.1M of shares on the open market and bought none.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.1M

5 insiders

Of sales under plans

99%

$0.1M

DateInsiderTradeSharesPriceValueFiling
Aug 17, 2026 Eric D. ShaffDirector Sold plan 263 $4.55 $0.0M Form 4
Aug 17, 2026 Kelly BradySee Remarks Sold plan 64 $4.55 $0.0M Form 4
Aug 17, 2026 Matthew R HennSee Remarks Sold plan 81 $4.55 $0.0M Form 4
Aug 17, 2026 Thomas DesRosierSee Remarks Sold plan 82 $4.55 $0.0M Form 4
May 18, 2026 Eric D. ShaffDirector Sold plan 259 $7.53 $0.0M Form 4
May 18, 2026 Kelly BradySee Remarks Sold 59 $7.53 $0.0M Form 4
May 18, 2026 Matthew R HennSee Remarks Sold plan 77 $7.53 $0.0M Form 4
May 18, 2026 Thomas DesRosierSee Remarks Sold plan 79 $7.53 $0.0M Form 4
Feb 15, 2026 Eric D. ShaffDirector Sold plan 259 $8.47 $0.0M Form 4
Feb 15, 2026 Matthew R HennSee Remarks Sold plan 89 $8.47 $0.0M Form 4
Feb 15, 2026 Teresa L. YoungSee Remarks Sold plan 75 $8.47 $0.0M Form 4
Feb 15, 2026 Thomas DesRosierSee Remarks Sold plan 78 $8.47 $0.0M Form 4
Nov 15, 2025 Eric D. ShaffDirector Sold plan 217 $17.30 $0.0M Form 4
Nov 15, 2025 Matthew R HennSee Remarks Sold plan 1,257 $17.30 $0.0M Form 4
Nov 15, 2025 Teresa L. YoungSee Remarks Sold plan 1,042 $17.30 $0.0M Form 4
Nov 15, 2025 Thomas DesRosierSee Remarks Sold plan 76 $17.30 $0.0M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Seres Therapeutics, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $291M$181M$128M$30.8M$45.8M
Debt incl. finance leases $24.1M$50.0M$110Mβ€”β€”
Debt / equity 0.2x4.6xβ€”β€”β€”
Interest coverage βˆ’22.2xβˆ’29.9xβˆ’79.1xβ€”β€”
Current ratio 3.7x2.3x1.8x0.9x2.6x
Quick ratio 3.7x2.3x1.5x0.9x2.6x
Total assets $355M$349M$359M$140M$138M
Total liabilities $223M$338M$403M$126M$94.0M
Shareholders' equity $132M$10.8Mβˆ’$44.9M$13.8M$44.2M
Net debt (βˆ’ = net cash) βˆ’$267Mβˆ’$131Mβˆ’$18.0Mβ€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Seres Therapeutics, Inc. passes 5 of 7 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ“ βœ“
Cash from operations is positive βœ“ βœ• βœ• βœ• βœ• βœ“ βœ• βœ• βœ• βœ“
Return on assets rose β€” βœ• βœ• βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ• βœ• βœ“ βœ“ βœ• βœ• βœ•
Debt fell relative to assets β€” β€” β€” β€” βœ“ βœ“ βœ• βœ• β€” β€”
Current ratio rose β€” βœ• βœ• βœ• βœ“ βœ• βœ• βœ• βœ• βœ“
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ• βœ“ βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” βœ“ βœ“ βœ“ βœ• βœ“ βœ• βœ• βœ• βœ“
F-score β€” / 32 / 72 / 72 / 73 / 85 / 81 / 82 / 82 / 75 / 7
Accruals ratio βˆ’49.7%βˆ’6.0%βˆ’23.3%4.9%1.9%βˆ’20.7%βˆ’6.1%1.0%59.7%3.3%
Altman Z'' 0.66βˆ’3.01βˆ’13.67βˆ’12.56βˆ’1.60βˆ’2.15βˆ’9.46βˆ’11.26βˆ’28.64βˆ’25.59

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $21.8M $32.1M $28.3M $34.5M $33.2M $145M $7.1M $0.0M $0.0M $0.8M
Net interest income $1.3M $1.6M β€” β€” β€” β€” β€” β€” β€” β€”
Research and development $82.0M $89.5M $96.0M $80.1M $90.6M $142M $110M $118M $64.6M $49.1M
Operating income βˆ’$92.8M βˆ’$91.4M βˆ’$100M βˆ’$71.9M βˆ’$88.1M βˆ’$64.5M βˆ’$180M βˆ’$195M βˆ’$121M βˆ’$94.0M
Interest expense β€” β€” β€” $0.5M $2.9M $2.9M $6.0M $2.5M $0.0M $0.0M
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Net income βˆ’$91.6M βˆ’$89.4M βˆ’$98.9M βˆ’$70.3M βˆ’$89.1M βˆ’$65.6M βˆ’$250M βˆ’$114M $0.1M $5.7M
Net income to common βˆ’$91.6M βˆ’$89.4M βˆ’$98.9M βˆ’$70.3M βˆ’$89.1M βˆ’$65.6M βˆ’$250M βˆ’$114M $0.1M $5.7M
Diluted EPS βˆ’$2.30 βˆ’$2.21 βˆ’$2.43 βˆ’$1.24 βˆ’$1.12 βˆ’$0.72 βˆ’$2.31 βˆ’$17.77 $0.00 $0.64
Diluted shares 0.04B 0.04B 0.04B 0.06B 0.08B 0.09B 0.11B 0.01B 0.01B 0.01B
Cash flow
Cash from operations $43.9M βˆ’$75.5M βˆ’$62.9M βˆ’$76.5M βˆ’$93.6M $6.7M βˆ’$229M βˆ’$117M βˆ’$149M $1.1M
Capital expenditure $21.5M $4.7M $1.9M $1.0M $0.6M $9.6M $9.8M $8.0M $0.4M $0.3M
Free cash flow $22.4M βˆ’$80.2M βˆ’$64.8M βˆ’$77.5M βˆ’$94.2M βˆ’$2.9M βˆ’$239M βˆ’$125M βˆ’$149M $0.9M
Depreciation and amortization $4.2M $7.3M $7.9M $7.6M $6.6M $5.9M $6.6M $6.2M $5.5M $4.1M
Stock-based compensation $16.9M $17.4M $16.6M $8.3M $8.8M $20.2M $25.5M $34.1M $21.0M $10.8M
Share buybacks β€” $0.0M β€” β€” β€” β€” β€” β€” β€” β€”
Dividends and buybacks β€” $0.0M β€” β€” β€” β€” β€” β€” β€” β€”
Balance sheet
Cash and short-term investments $193M $150M $85.8M $94.8M $254M $291M $181M $128M $30.8M $45.8M
Total debt β€” β€” β€” $25.0M $25.0M $24.1M $50.0M $110M β€” β€”
Current assets $198M $155M $92.7M $100M $269M $304M $195M $175M $38.7M $49.4M
Current liabilities $30.5M $31.6M $42.0M $46.0M $46.4M $82.3M $85.6M $98.7M $41.2M $19.3M
Inventory β€” β€” β€” β€” β€” β€” $0.0M $29.6M β€” β€”
Property and equipment, net $36.1M $32.9M $26.3M $19.5M $13.9M $17.9M $23.0M $17.6M $11.5M $7.6M
Total assets $273M $190M $120M $132M $343M $355M $349M $359M $140M $138M
Total liabilities $140M $129M $169M $181M $168M $223M $338M $403M $126M $94.0M
Preferred stock β€” β€” β€” β€” β€” $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $133M $60.7M βˆ’$48.0M βˆ’$48.3M $175M $132M $10.8M βˆ’$44.9M $13.8M $44.2M
Margins
Operating margin βˆ’426.5% βˆ’284.7% βˆ’354.8% βˆ’208.3% βˆ’265.3% βˆ’44.5% βˆ’2,524.0% β€” β€” βˆ’11,910.1%
EBITDA margin βˆ’407.2% βˆ’262.1% βˆ’327.0% βˆ’186.3% βˆ’245.5% βˆ’40.4% βˆ’2,431.0% β€” β€” βˆ’11,386.3%
Net margin βˆ’420.7% βˆ’278.4% βˆ’350.0% βˆ’203.7% βˆ’268.3% βˆ’45.2% βˆ’3,509.5% β€” β€” 721.9%
FCF margin 103.0% βˆ’249.8% βˆ’229.2% βˆ’224.7% βˆ’283.6% βˆ’2.0% βˆ’3,347.9% β€” β€” 109.6%
Net interest share of revenue 5.8% 5.0% β€” β€” β€” β€” β€” β€” β€” β€”
Returns
Return on capital employed βˆ’38.3% βˆ’57.9% βˆ’127.9% βˆ’83.1% βˆ’29.7% βˆ’23.7% βˆ’68.4% βˆ’75.1% βˆ’123.1% βˆ’79.1%
Return on equity βˆ’69.0% βˆ’92.5% βˆ’1,563.8% β€” βˆ’141.0% βˆ’42.8% βˆ’351.6% β€” β€” 19.6%
Return on assets βˆ’33.6% βˆ’38.7% βˆ’63.8% βˆ’55.6% βˆ’37.5% βˆ’18.8% βˆ’71.1% βˆ’32.2% 0.1% 4.1%
Return on tangible equity βˆ’69.0% βˆ’147.3% β€” β€” βˆ’51.0% βˆ’49.9% βˆ’2,319.9% β€” 1.0% 12.9%
Growth
Revenue growth β€” 47.5% βˆ’11.9% 22.1% βˆ’3.7% 336.3% βˆ’95.1% βˆ’100.0% β€” β€”
Net income growth β€” β€” β€” β€” β€” β€” β€” β€” β€” 4,088.2%
FCF growth β€” βˆ’457.6% β€” β€” β€” β€” β€” β€” β€” β€”
Share count change β€” 1.5% 0.7% 39.0% 40.8% 14.9% 17.9% βˆ’94.1% 21.4% 14.2%
Financial health
Debt / equity β€” β€” β€” β€” 0.1x 0.2x 4.6x β€” β€” β€”
Interest coverage β€” β€” β€” βˆ’143.2x βˆ’30.1x βˆ’22.2x βˆ’29.9x βˆ’79.1x β€” β€”
Current ratio 6.5x 4.9x 2.2x 2.2x 5.8x 3.7x 2.3x 1.8x 0.9x 2.6x
Quick ratio 6.5x 4.9x 2.2x 2.2x 5.8x 3.7x 2.3x 1.5x 0.9x 2.6x
Capital allocation
Capex / revenue 98.7% 14.6% 6.9% 2.9% 1.8% 6.6% 137.8% β€” β€” 31.9%
Stock comp / revenue 77.4% 54.1% 58.9% 24.2% 26.6% 14.0% 357.5% β€” β€” 1,373.9%
Quality scores
Piotroski F-score β€” 2.0 2.0 2.0 3.0 5.0 1.0 2.0 2.0 5.0
Altman Z'' 0.7 βˆ’3.0 βˆ’13.7 βˆ’12.6 βˆ’1.6 βˆ’2.2 βˆ’9.5 βˆ’11.3 βˆ’28.6 βˆ’25.6
Accruals ratio βˆ’49.7% βˆ’6.0% βˆ’23.3% 4.9% 1.9% βˆ’20.7% βˆ’6.1% 1.0% 59.7% 3.3%

Source: SEC EDGAR XBRL filings (CIK 0001609809). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open